Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback

NEUROCRINE BIOSCIENCES INC

2024-Q3 EPS reported $2.29 revenue$1,727,600,000

INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.
Total revenues $622.1M (+25% YoY); GAAP EPS $1.24 vs $0.82; Non-GAAP EPS $1.81 vs $1.54.
Board authorized $300M share repurchase plan; intends to enter accelerated share repurchase.
New CEO Kyle W. Gano appointed effective Oct 11, 2024; Phase 2 data for NBI-1117568 triggered $35M milestone.
Terminated licenses for luvadaxistat (CIAS) and NBI-827104; terminations expected in 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.